Ardelyx, Inc.

Contributing Author

Recent Articles by Ardelyx, Inc.

Jul-23	Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026 ARDX GlobeNewswire
May-19	Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026 ARDX GlobeNewswire
May-07	Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings ARDX GlobeNewswire
Apr-30	Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update ARDX +5.32% ARDX +8.69% GlobeNewswire
Apr-27	Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings ARDX GlobeNewswire
Apr-23	Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026 ARDX GlobeNewswire
Apr-20	Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer ARDX GlobeNewswire
Apr-16	Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026 ARDX GlobeNewswire
Apr-01	Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx ARDX GlobeNewswire
Mar-12	Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award ARDX -5.51% GlobeNewswire
Mar-09	Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C ARDX GlobeNewswire
Mar-04	Ardelyx to Participate in Upcoming Investor Conferences ARDX +6.91% GlobeNewswire
Feb-24	Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions ARDX +14.09% GlobeNewswire
Feb-19	Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update ARDX ARDX -14.99% GlobeNewswire
Feb-05	Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026 ARDX -5.15% GlobeNewswire
Feb-03	Ardelyx Receives New Patent for Tenapanor ARDX GlobeNewswire
Jan-28	First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA ARDX GlobeNewswire
Jan-08	Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook ARDX +20.07% GlobeNewswire
Nov-07	Real-World Evidence Studies of XPHOZAH (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week ARDX GlobeNewswire
Nov-05	Ardelyx to Participate at the Jefferies Global Healthcare Conference in London ARDX +6.25% GlobeNewswire
Nov-04	Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference ARDX -5.41% GlobeNewswire
Oct-30	Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update ARDX ARDX +20.96% GlobeNewswire
Oct-28	Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting ARDX GlobeNewswire
Oct-21	Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week ARDX GlobeNewswire
Oct-13	Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025 ARDX GlobeNewswire
Oct-13	Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer ARDX GlobeNewswire
Aug-25	Ardelyx to Participate in Upcoming Investor Conferences ARDX GlobeNewswire
Aug-04	Ardelyx Announces Changes to the Executive Leadership Team ARDX ARDX +16.86% GlobeNewswire
Aug-04	Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update ARDX ARDX +16.86% GlobeNewswire
Jul-21	Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025 ARDX GlobeNewswire
Jun-02	Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer ARDX GlobeNewswire
May-21	Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025 ARDX GlobeNewswire
May-06	Ardelyx Presents Data Supporting IBSRELA (tenapanor) at Digestive Disease Week 2025 Conference ARDX +5.76% GlobeNewswire
May-01	Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update ARDX ARDX -24.50% GlobeNewswire

Ardelyx, Inc.

Recent Articles by Ardelyx, Inc.

Upgrade your Finviz experience